BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND PSA
2181 results:

  • 1. Salvage Radiotherapy PSMA PET/CT-guided in Men With psa Recurrence.
    Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
    Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A pictorial view on false positive findings of
    Dancheva Z; Chausheva S; Stoeva T; Dyankova M; Yordanova T; Chaushev B; Marinov R; Nikolov V; Abushev P; Todorov G; Dimitrova E; Klisarova A; Anakievski D
    Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [
    Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
    Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Risk factor analysis and nomogram construction in patients with distant metastatic prostate cancer at different psa levels: a study based on the SEER database.
    Li HD; Fan SQ; Qin F; Zhao ST; Kong SP; Ma JG
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2372-2386. PubMed ID: 38567600
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [
    Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
    Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Role of bone Scan Index (BSI) in the Prognosis and Treatment Efficacy in Castration-Sensitive Prostate cancer Patients with bone Metastasis].
    Deguchi K; Sasaki T; Oue H; Okamoto T; Kato M; Kajiwara S; Higashi S; Masui S; Nishikawa K; Inoue T
    Hinyokika Kiyo; 2024 Feb; 70(2):29-37. PubMed ID: 38447942
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
    Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
    Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Metastatic PSMA avid prostate tumour with penile uptake; a rare metastatic site on PET-CT.
    Waqas M; Sajid T; Razi M
    J Pak Med Assoc; 2024 Feb; 74(2):407-408. PubMed ID: 38419250
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Pluvicto-Induced 18 F-PSMA PET bone Flare.
    Wang X; Martin D; Hogan T; Veselicky K
    Clin Nucl Med; 2024 Apr; 49(4):342-343. PubMed ID: 38389206
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
    Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
    Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Analysis of Factors Influencing bone Metastasis in Prostate cancer and Diagnostic Value of Serum psa, CysC and D-D.
    Liu X; Zhao C; Lin J; Liu B
    Arch Esp Urol; 2024 Jan; 77(1):72-78. PubMed ID: 38374016
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Ductal prostate cancer staging: Role of PSMA PET/CT.
    Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
    Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate cancer.
    Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
    Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.
    Cui Y; Lin J; Sun D; Zhang H; Diao T; Fu Q
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):45. PubMed ID: 38281261
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
    Saylor PJ; Kozin SV; Matsui A; Goldberg SI; Aoki S; Shigeta K; Mamessier E; Smith MR; Michaelson MD; Lee RJ; Duda DG
    Radiother Oncol; 2024 Mar; 192():110091. PubMed ID: 38224917
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
    Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
    BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Fluorine-18 prostate-specific membrane antigen-1007-avid indeterminate bone lesions in prostate cancer: clinical and PET/CT features to predict outcomes and prognosis.
    Luo L; Wang Z; Wang X; Gao J; Zheng A; Duan X
    Clin Radiol; 2024 May; 79(5):346-353. PubMed ID: 38216370
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Diagnostic accuracy of bone scan at different psa levels in biochemical recurrence of prostate cancer.
    Singh KB; London KI; Wong VCK; Mansberg R
    J Med Imaging Radiat Sci; 2024 Mar; 55(1):91-96. PubMed ID: 38216344
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The Prognostic Role of Preoperative PSMA PET/CT in cN0M0 pN+ Prostate cancer: A Multicenter Study.
    Marra G; Rajwa P; Filippini C; Ploussard G; Montefusco G; Puche-Sanz I; Olivier J; Zattoni F; Moro FD; Magli A; Dariane C; Affentranger A; Grogg JB; Hermanns T; Chiu PK; Malkiewicz B; Kowalczyk K; Van den Bergh RCN; Shariat SF; Bianchi A; Antonelli A; Gallina S; Berchiche W; Sanchez-Salas R; Cathelineau X; Afferi L; Fankhauser CD; Mattei A; Karnes RJ; Scuderi S; Montorsi F; Briganti A; Deandreis D; Gontero P; Gandaglia G;
    Clin Genitourin Cancer; 2024 Apr; 22(2):244-251. PubMed ID: 38155081
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
    Yokomizo A; Shiota M; Morokuma F; Eto M; Matsuyama H; Matsumoto H; Kamoto T; Terada N; Kawahara K; Enokida H; Tatarano S; Fujimoto N; Higasijima K; Sakai H; Hakariya T; Igawa T; Suekane S; Kamba T; Sugiyama Y; Kishimoto J; Naito S
    Int J Urol; 2024 Apr; 31(4):362-369. PubMed ID: 38148124
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 110.